BioDirection is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the Tbit blood test, delivers biologically-based results shown to accurately confirm a concussion in less than 90 seconds. BioDirection's platform system utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/04/16 | $4,000,000 | Series B |
Provident Healthcare Ventures | undisclosed |
| 07/02/20 | $18,000,000 | Series C |
Shepherd Kaplan Krochuk | undisclosed |
